Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease

Nature Reviews Neuroscience

Volumn 1, Issue 2, 2000, Pages 109-115

  Gusella, James F ^a   MacDonald, Marcy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; POLYGLUTAMINE;

ANIMAL; DEGENERATIVE DISEASE; GENOTYPE; HUMAN; METHODOLOGY; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; REVIEW;

ANIMALS; GENOTYPE; HUMANS; MOLECULAR BIOLOGY; NEURODEGENERATIVE DISEASES; PEPTIDES; PHENOTYPE;

EID: 0034329159     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/35039051     Document Type: Article

References (98)

1. Goldfarb, L. G. et al. Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann. Neuroi. 39, 500-506 (1996).
2. Gusella, J. F. et al. Huntington's disease. CoidSpring Harb. Symp.Quant. Bioi. 61, 615-626 (1996).
3. 1A voltage-dependent calcium channel gene and clinical variations in Japanese population. Ann. Neuroi. 42, 879-884 (1997).
4. Lang, A. E., Rogaeva, E. A., Tsuda, T., Hutterer, J. & St George-Hyslop, P. Homozygous inheritance of the Machado- Joseph disease gene. Ann. Neurol. 36, 443-447 (1994).
5. Lerer, I., Merims, D., Abeliovich, D., Zlotogora, J. & Gadoth, N. Machado-Joseph disease: correlation between the clinical features, the CAG repeat length and homozygosity for the mutation. Eur. J. Hum. Genet. 4, 3-7 (1996).
6. Sanpei, K. et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nature Genet. 14, 277-284 (1996).
7. Sato, K. et al. Does homozygosity advance the onset of dentatorubral-nallidoluycian atrophy? Neurology 45, 1934-1936 (1995).
8. Sobue, G. et al. Homozygosity for Machado-Joseph disease gene enhances phenotypic severity. J. Neuroi. Neurosurg. Psychiat. 60, 354-356 (1996).
9. Takiyama, Y. et al. A Japanese family with spinocerebellar ataxia type 6 which includes three individuals homozygous for an expanded CAG repeat in the SCA6/CACNL1A4 gene. J. Neurol. Sci. 158, 141-147 (1998).
10. Matsuyama, Z. et al. Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6). Hum. Moi. Genet. 6, 1283-1287 (1997).
11. Kato, T. et al. Sisters homozygous for the spinocerebellar ataxia type 6 (SCA6)/CACNA1A gene associated with different clinical nhenotynec. Clin. Genet. 58, 69-73 (2000).
12. Vonsattel, J. P. Neuropathology of Huntington's disease. Neurosci. News 3, 45-48 (2000).
13. Furtado, S. et al. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann. Neurol. 39, 132-136 (1996).
14. Penney, J. B. Jr, Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41, 689-692 (1997).
15. Gusella, J. F., Persichetti, F. & MacDonald, M. E. The genetic defect causing Huntington's disease: repeated in other contexts? Mol. Med. 3, 238-246 (1997).
16. Kieburtz, K. et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J. Med. Genet. 31, 872-874 (1994).
17. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
18. Huang, C. C. et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell. Mol. Genet. 24, 217-233 (1998).
19. Perutz, M. F., Johnson, T, Suzuki, M. & Finch, J. T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. NatiAcad. Sci. USA 91, 5355-5358 (1994).
20. Grunewald, T. & Beal, M. F. Bioenergetics in Huntington's disease. Ann. NY Acad. Sci. 893, 203-213 (1999).
21. Narain, Y., Wyttenbach, A., Rankin, J., Furlong, R. A. & Rubinsztein, D. C. A molecular investigation of true dominance in Huntington's disease. J. Med. Genet. 36, 739-746 (1999).
22. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 81, 493-506 (1996).
23. Hackam, A. S. et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141, 1097-1105 (1998).
24. Kuemmerle, S. et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849 (1999).
25. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice Cell 95, 41-53 (1998).
26. Lunkes, A. & Mandel, J. L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 1, 1355-1361 (1998).
27. Persichetti, F. et al. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Neurobiol. Dis. 6, 364-375 (1999)
28. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66 (1998).
29. Cooper, J. K. et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 1, 783-790 (1998).
30. Kim, M. et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19, 964-973 (1999).
31. Sato, A. et al. Adenovirus-mediated expression of mutant DRPLA proteins with expanded polyglutamine stretches in neuronally differentiated PC12 cells. Preferential intranuclear aggregate formation and apoptosis. Hum. Mol. Genet. 8, 997-1006 (1999).
32. Simeoni, S. et al. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. 9, 133-144 (2000).
33. Cummings, C. J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genet. 19, 148-154 (1998).
34. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
35. Chai, Y., Koppenhafer, S. L., Shoesmith, S. J., Perez, M. K. & Paulson, H. L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 8, 673-682 (1999).
36. Stenoien, D. L. et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8, 731-741 (1999).
37. Wyttenbach, A. et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. NatiAcad. Sci. USA 91, 2898-2903 (2000).
38. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
39. Hurlbert, M. S. et al. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48, 649-651 (1999).
40. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000).
41. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 211, 1990-1993 (1997).
42. Rubinsztein, D. C., Wyttenbach, A. & Rankin, J. Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? J. Med. Genet. 36, 265-270 (1999).
43. Burright, E. N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948 (1995).
44. Bingham, P. M. et al. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nature Genet. 9, 191-196 (1995).
45. Ikeda, H. et al. Expanded polyglutamine in the Machado- Joseph disease protein induces cell death in vitro and in vivo. Nature Genet. 13, 196-202 (1996).
46. Schilling, G. et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24, 275-286 (1999).
47. Sato, T. et al. Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum. Mol. Genet. 8, 99-106 (1999).
48. Reddy, P H. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genet. 20, 198-202 (1998).
49. Hodgson, J. G. et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192 (1999).
50. Lorenzetti, D. et al. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum. Mol. Genet. 9, 779-785 (2000).
51. Wheeler, V. C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999).
52. Shelbourne, P. F. et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8, 763-774 (1999).
53. Levine, M. S. et al. Enhanced sensitivity to N-methyl-D- aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515-532 (1999).
54. Usdin, M. T., Shelbourne, P. F., Myers, R. M. & Madison, D. V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 8, 839-846 (1999).
55. Menalled, L. et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 162, 328-342 (2000).
56. Wheeler, V. C. et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9, 503-513 (2000).
57. Nance, M. A., Mathias-Hagen, V., Breningstall, G., Wick, M. J. & McGlennen, R. C. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 52, 392-394 (1999).
58. Heiser, V. et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl Acad. Sci. USA 91, 6739-6744 (2000).
59. Nagai, Y. et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 215, 10437-10442 (2000).
60. Wellington, C. L. & Hayden, M. R. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet. 51, 1-10 (2000).
61. Satyal, S. H. et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis eiegans. Proc. Natl Acad. Sci. USA 91, 5750-5755 (2000).
62. Kobayashi, Y. et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 215, 8772-8778 (2000).
63. Krobitsch, S. & Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl Acad. Sci. USA 91, 1589-1594 (2000).
64. Kazemi-Esfarjani, P. & Benzer, S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 281, 1837-1840 (2000).
65. Warrick, J. M. et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophiia by the molecular chaperone HSP70. Nature Genet. 23, 425-428 (1999).
66. Muchowski, P. J. et al. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloidlike fibrils. Proc. Nati Acad. Sci. USA 91, 7841-7846 (2000).
67. Bachoud-Levi, A. et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp. Neurol. 161, 194-202 (2000).
68. Magavi, S. S., Leavitt, B. R. & Macklis, J. D. Induction of neurogenesis in the neocortex of adult mice. Nature 405, 951-955 (2000).
69. van Dellen, A., Blakemore, C., Deacon, R., York, D. & Hannan, A. J. Delaying the onset of Huntington's in mice. Nature 404, 721-722 (2000).
70. Ona, V. O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
71. Ferrante, R. J. et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397 (2000).
72. Chen, M. et al. Minocycline inhibits caspase-1 and caspase- 3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med. 6, 797-801 (2000).
73. Jackson, G. R. et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophiia photoreceptor neurons. Neuron 21, 633-642 (1998).
74. Warrick, J. M. et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93, 939-949 (1998).
75. Faber, P. W., Alter, J. R., MacDonald, M. E. & Hart, A. C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis eiegans sensory neuron. Proc. Natl Acad. Sci. USA 96, 179-184 (1999).
76. Marsh, J. L. et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophiia. Hum. Mol. Genet. 9, 13-25 (2000).
77. Rubinsztein, D. C. et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc. Natl Acad. Sci. USA 94, 3872-3876 (1997).
78. MacDonald, M. E. et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 53, 1330-1332 (1999).
79. Farrer, L. A. et al. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am. J. Hum. Genet. 53, 125-130 (1993).
80. DeStefano, A. L. et al. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am. J. Hum. Genet. 59, 119-127 (1996).
81. Ranum, L. P. et al. Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am. J. Hum. Genet. 55, 244-252 (1994).
82. Shizuka, M. et al. Spinocerebellar ataxia type 6: CAG trinucleotide expansion, clinical characteristics and sperm analysis. Eur. J. Neurol. 5, 381-387 (1998).
83. Schols, L. et al. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J. Neurol. Neurosurg. Psychiatry 64, 67-73 (1998).
84. Nagai, Y. et al. Clinical and molecular genetic study in seven Japanese families with spinocerebellar ataxia type 6. J. Neurol. Sci. 151, 52-59 (1998).
85. Matsumura, R. et al. Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the CAG repeat expansion. Neurology 49, 1238-1243 (1997).
86. Kim, J. M. et al. Spinocerebellar ataxia type 2 in seven Korean families: CAG trinucleotide expansion and clinical characteristics. J. Korean Med. Sci. 14, 659-664 (1999).
87. Gouw, L. G. et al. Analysis of the dynamic mutation in the SCA7 gene shows marked parental effects on CAG repeat transmission. Hum. Mol. Genet. 1, 525-532 (1998).
88. David, G. et al. Molecular and clinical correlations in auto- somal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum. Mol. Genet. 1, 165-170 (1998).
89. Johansson, J. et al. Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. Hum. Mol. Genet. 1, 171-176 (1998).
90. Benton, C. S. et al. Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype. Neurology 51, 1081-1086 (1998).
91. Giunti, P et al. Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation. Am. J. Hum. Genet. 64, 1594-1603 (1999).
92. Martin, J., Van Regemorter, N., Del-Favero, J., Lofgren, A. & Van Broeckhoven, C. Spinocerebellar ataxia type 7 (SCA7) — correlations between phenotype and genotype in one large Belgian family. J. Neurol. Sci. 168, 37-46 (1999).
93. Igarashi, S. et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 42, 2300-2302 (1992).
94. La Spada, A. R. et al. Meiotic stability and genotype- phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nature Genet. 2, 301-304 (1992).
95. Shimada, N. et al. X-linked recessive bulbospinal neurono- pathy: clinical phenotypes and CAG repeat size in androgen receptor gene. Muscie Nerve 18, 1378-1384 (1995).
96. Filla, A. et al. Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families. J. Neurol. 246, 467-471 (1999).
97. Moseley, M. L. et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 51, 1666-1671 (1998).
98. Riess, O. et al. SCA2 trinucleotide expansion in German SCA patients. Neurogenetics 1, 59-64 (1997).